17P Injection (Makena)

On February 4, 2011, The US Food and Drug Administration approved hydroxyprogesterone caproate injection, Trade name Makena, to reduce the risk for preterm delivery before 37 weeks of pregnancy in women with singleton pregnancy and a history of at least 1 spontaneous preterm birth. This is the first drug approved specifically to reduce this risk.

Upon FDA Approval, K-V Pharmaceuticals/Ther-RX dramatically increased the cost of 17P from approximately $10/injection to $1500/injection, thus raising the cost for treatment for 20 injections from approximately $200 to %30,000. Physicians, pregnancy organizations and patients alike are outraged.

While K-V Pharmaceuticals/Ther-RX  has not budged on its price, they have instituted an assistance program for those unable to afford Makena as part of their Makena Care Connection, a one stop resource for patients. Here is a summary of the program provided by KeepEmCookin.com.

The financial support program for Makena offers assistance to both uninsured and insured patients, and is based on income. According to K-V Pharmaceutical:

Insured patients with annual household incomes of up to $100,000 who apply for and are eligible for co-pay assistance will have a co-pay of $20 or less per injection for Makena.

Uninsured patients with annual household incomes of up to $60,000 who apply for and are eligible for patient assistance will receive Makena at no cost. Uninsured patients with annual household incomes between $60,000 and $100,000 will be able to acquire Makena at a cost that is comparable to the average co-pay assigned by commercial insurance plans.

Makena will not be carried by retail pharmacies. The prescription process for Makena will be managed by the Makena Care Connection, which is available by calling 1-800-847-3418 from 8 a.m. to 9 p.m. EST, Monday through Friday.